FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2557325932> ?p ?o ?g. }

• W2557325932 abstract "Abstract HHT is a cephalotaxus alkaloid obtained from an evergreen tree that inhibits the synthesis of proteins leading to apoptosis. HHT by intravenous (IV) administration has demonstrated significant activity in pts with CML after failure to interferon (IFN) therapy, with cytogenetic (CG) responses in 30% of cases. A phase I study of SC HHT previously reported in pts in accelerated or blast phase (before imatinib was available), demonstrated efficacy (5 of 10 responses) and adequate tolerance at the same doses used IV. We thus started a phase II study to determine the activity of SC HHT in pts with CML in late CP after imatinib failure. Therapy with HHT consisted of an initial IV loading dose of 2.5 mg/m2 over 24 h, followed by 1.25 mg/m2 SC twice daily for 14 days every 28 days. Six pts have been treated and 5 are evaluable (1 pt lost to follow-up after 1 cycle). Best response to prior imatinib therapy for a median of 64 weeks (range, 12 to 96) was: complete hematologic response (CHR) in 3 pts and complete CG response (CG CR) in 2, and primary resistance in 1 pt. All 5 evaluable pts had also failed IFN, and other therapies: Ara-C (n=2), farnesyl transferase inhibitors (n=2). At the time HHT was started, all had lost CHR. Median age was 52.5 years (range, 36 to 66), time from diagnosis to treatment 58 months (18 to 164), WBC 24.35 x 109/L (6/4 to 43), platelets 308 x 109/L (147 to 536), and peripheral basophils 4/5% (3% to 17%). Mutations of the BCR-ABL kinase domain were identified in 2 pts (2 mutations each: G250E and Y253H in one, D276G and F359I the other). Pts received a median of 4.5 courses of SC HHT (range, 1 to 5). CHR was achieved in all 5 evaluable pts. Of these, 1 achieved a CG CR and a minor CG response (lowest Ph 80% and 90%, respectively). The pt that achieved CG CR had D286G and F359I mutations before therapy with HHT. Interestingly, this pt developed extramedullary blast disease (bones) that required radiotherapy while remaining in CG CR in peripheral blood and bone marrow. All pts developed myelosuppression and 3 had their HHT dose reduced due to prolonged neutropenia. Grade 3–4 non-hematologic toxicity included neutropenic fever (n=1), and fatigue (n=1). We conclude that SC HHT is well tolerated and may have clinical activity in pts with CML after imatinib failure. This study was terminated because of drug availability from this source; a new trial will be conducted obtaining HHT from a different sponsor." @default.
• W2557325932 created "2016-12-08" @default.
• W2557325932 creator A5015101485 @default.
• W2557325932 creator A5019337932 @default.
• W2557325932 creator A5042706821 @default.
• W2557325932 creator A5084290698 @default.
• W2557325932 creator A5085521139 @default.
• W2557325932 creator A5090435894 @default.
• W2557325932 date "2005-11-16" @default.
• W2557325932 modified "2023-10-15" @default.
• W2557325932 title "Subcutaneous (SC) Homoharringtonine (HHT) for Patients (pts) with Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP) after Imatinib Mesylate Failure." @default.
• W2557325932 doi "https://doi.org/10.1182/blood.v106.11.4839.4839" @default.
• W2557325932 hasPublicationYear "2005" @default.
• W2557325932 type Work @default.
• W2557325932 sameAs 2557325932 @default.
• W2557325932 citedByCount "2" @default.
• W2557325932 crossrefType "journal-article" @default.
• W2557325932 hasAuthorship W2557325932A5015101485 @default.
• W2557325932 hasAuthorship W2557325932A5019337932 @default.
• W2557325932 hasAuthorship W2557325932A5042706821 @default.
• W2557325932 hasAuthorship W2557325932A5084290698 @default.
• W2557325932 hasAuthorship W2557325932A5085521139 @default.
• W2557325932 hasAuthorship W2557325932A5090435894 @default.
• W2557325932 hasConcept C126322002 @default.
• W2557325932 hasConcept C141071460 @default.
• W2557325932 hasConcept C2776694085 @default.
• W2557325932 hasConcept C2776960273 @default.
• W2557325932 hasConcept C2777583451 @default.
• W2557325932 hasConcept C2778461978 @default.
• W2557325932 hasConcept C2778729363 @default.
• W2557325932 hasConcept C2780829020 @default.
• W2557325932 hasConcept C2781057849 @default.
• W2557325932 hasConcept C2910157418 @default.
• W2557325932 hasConcept C3019892230 @default.
• W2557325932 hasConcept C31760486 @default.
• W2557325932 hasConcept C71924100 @default.
• W2557325932 hasConcept C89560881 @default.
• W2557325932 hasConcept C90924648 @default.
• W2557325932 hasConceptScore W2557325932C126322002 @default.
• W2557325932 hasConceptScore W2557325932C141071460 @default.
• W2557325932 hasConceptScore W2557325932C2776694085 @default.
• W2557325932 hasConceptScore W2557325932C2776960273 @default.
• W2557325932 hasConceptScore W2557325932C2777583451 @default.
• W2557325932 hasConceptScore W2557325932C2778461978 @default.
• W2557325932 hasConceptScore W2557325932C2778729363 @default.
• W2557325932 hasConceptScore W2557325932C2780829020 @default.
• W2557325932 hasConceptScore W2557325932C2781057849 @default.
• W2557325932 hasConceptScore W2557325932C2910157418 @default.
• W2557325932 hasConceptScore W2557325932C3019892230 @default.
• W2557325932 hasConceptScore W2557325932C31760486 @default.
• W2557325932 hasConceptScore W2557325932C71924100 @default.
• W2557325932 hasConceptScore W2557325932C89560881 @default.
• W2557325932 hasConceptScore W2557325932C90924648 @default.
• W2557325932 hasLocation W25573259321 @default.
• W2557325932 hasOpenAccess W2557325932 @default.
• W2557325932 hasPrimaryLocation W25573259321 @default.
• W2557325932 hasRelatedWork W1996332917 @default.
• W2557325932 hasRelatedWork W2013230304 @default.
• W2557325932 hasRelatedWork W2038119532 @default.
• W2557325932 hasRelatedWork W2072008804 @default.
• W2557325932 hasRelatedWork W2079968296 @default.
• W2557325932 hasRelatedWork W2417473921 @default.
• W2557325932 hasRelatedWork W2549797588 @default.
• W2557325932 hasRelatedWork W2564546069 @default.
• W2557325932 hasRelatedWork W2738032586 @default.
• W2557325932 hasRelatedWork W2965804240 @default.
• W2557325932 isParatext "false" @default.
• W2557325932 isRetracted "false" @default.
• W2557325932 magId "2557325932" @default.
• W2557325932 workType "article" @default.